Encycle Therapeutics is a University of Toronto spin‑off drug discovery company developing the nacellin platform chemistry to generate membrane‑permeable, orally bioavailable scaffolds for targeting protein–protein interactions. Its lead program is a non‑immunogenic, orally bioavailable inhibitor of integrin alpha‑4‑beta‑7 for inflammatory bowel disease. The company has generated several nacellin scaffolds and is advancing a pipeline of novel therapeutics. Encycle has active research collaborations with major pharmaceutical companies including AstraZeneca, GSK, Merck, Pfizer and Takeda. It intends to use new funding to further develop its platform and pipeline, expand research collaborations, and position itself for a Series A and/or strategic partnerships. Dr. Jeffrey Coull serves as president and CEO, and the company was created in partnership with MaRS Innovation.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2015